|
JP5924834B2
(ja)
|
2008-09-02 |
2016-05-25 |
アマリン ファーマシューティカルズ アイルランド リミテッド |
エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法
|
|
KR20110091680A
(ko)
*
|
2008-10-17 |
2011-08-12 |
메타볼렉스, 인코포레이티드 |
작고 조밀한 ｌｄｌ 입자를 감소시키는 방법
|
|
NZ734905A
(en)
|
2009-04-29 |
2019-05-31 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
HUE034941T2
(en)
|
2009-04-29 |
2018-03-28 |
Amarin Pharmaceuticals Ie Ltd |
Stable pharmaceutical composition and methods of using same
|
|
EP3318255B1
(en)
|
2009-06-15 |
2021-03-10 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating stroke in a subject on concomitant statin therapy
|
|
MX2012003555A
(es)
|
2009-09-23 |
2012-07-03 |
Amarin Corp Plc |
Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
|
|
WO2011140441A2
(en)
|
2010-05-06 |
2011-11-10 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
WO2012074930A2
(en)
|
2010-11-29 |
2012-06-07 |
Amarin Pharma, Inc. |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
US20130131170A1
(en)
|
2011-11-07 |
2013-05-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
US9827219B2
(en)
|
2012-01-06 |
2017-11-28 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject
|
|
MX392694B
(es)
|
2012-06-29 |
2025-03-24 |
Amarin Pharmaceuticals Ie Ltd |
Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina
|
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
US9814733B2
(en)
*
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
|
US10272058B2
(en)
|
2014-03-20 |
2019-04-30 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
JP6568577B2
(ja)
|
2014-03-20 |
2019-08-28 |
サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
肝内胆汁うっ滞症の治療
|
|
PH12016501978B1
(en)
*
|
2014-04-11 |
2023-07-12 |
Cymabay Therapeutics Inc |
Treatment of nafld and nash
|
|
EP3712254A1
(en)
|
2014-05-28 |
2020-09-23 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into gastric tissues through directed differentiation
|
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
|
EP3207123A1
(en)
|
2014-10-17 |
2017-08-23 |
Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center |
In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
|
|
CA2980296A1
(en)
*
|
2015-03-26 |
2016-09-29 |
T3D Therapeutics, Inc. |
Methods of treating liver disease using indane acetic acid derivatives
|
|
KR20240033300A
(ko)
|
2015-04-28 |
2024-03-12 |
바스프 에이에스 |
비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
|
|
WO2017049157A1
(en)
|
2015-09-18 |
2017-03-23 |
Duke University |
Methods and compositions for the treatment of steatosis-associated disorders
|
|
WO2017139708A1
(en)
|
2016-02-10 |
2017-08-17 |
Synlogic, Inc. |
Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
|
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
US12053445B2
(en)
|
2016-03-31 |
2024-08-06 |
Genfit |
Methods of treatment of cholestatic diseases
|
|
WO2017192997A1
(en)
|
2016-05-05 |
2017-11-09 |
Children's Hospital Medical Center |
Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
|
|
GB201614455D0
(en)
|
2016-08-24 |
2016-10-05 |
Univ Oxford Innovation Ltd |
Biomarkers
|
|
EP3534919A4
(en)
*
|
2016-11-04 |
2020-11-11 |
Children's Hospital Medical Center |
Liver organoid compositions and methods of making and using same
|
|
US10493363B2
(en)
*
|
2016-11-09 |
2019-12-03 |
Activision Publishing, Inc. |
Reality-based video game elements
|
|
KR102807995B1
(ko)
|
2016-12-05 |
2025-05-16 |
칠드런즈 호스피탈 메디칼 센터 |
결장 유사장기 및 이를 제조 및 사용하는 방법
|
|
US12281334B2
(en)
|
2017-04-14 |
2025-04-22 |
Children's Hospital Medical Center |
Multi donor stem cell compositions and methods of making same
|
|
US11000491B2
(en)
|
2017-05-05 |
2021-05-11 |
Hepanova, Inc. |
Amino-aryl-benzamide compounds and methods of use thereof
|
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US10512622B2
(en)
|
2017-07-14 |
2019-12-24 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
WO2019053582A1
(en)
|
2017-09-13 |
2019-03-21 |
Novartis Ag |
COMBINATIONS HAVING FXR AGONISTS
|
|
CA3077442A1
(en)
|
2017-10-10 |
2019-04-18 |
Children's Hospital Medical Center |
Esophageal tissue and/or organoid compositions and methods of making same
|
|
WO2019083070A1
(ko)
*
|
2017-10-27 |
2019-05-02 |
주식회사 삼양사 |
비알코올성 지방간 질환의 예방 또는 개선용 조성물
|
|
BR112020011431A2
(pt)
|
2017-12-06 |
2020-11-24 |
Basf As |
derivados de ácido graxo para o tratamento de esteato-hepatite não alcoólica
|
|
WO2019126626A1
(en)
|
2017-12-21 |
2019-06-27 |
Children's Hospital Medical Center |
Digitalized human organoids and methods of using same
|
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
|
SG11202100533VA
(en)
|
2018-07-26 |
2021-02-25 |
Childrens Hospital Med Ct |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
WO2020056158A1
(en)
|
2018-09-12 |
2020-03-19 |
Children's Hospital Medical Center |
Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
|
|
JP7020756B2
(ja)
|
2018-09-24 |
2022-02-16 |
アマリン ファーマシューティカルズ アイルランド リミテッド |
対象の心血管イベントのリスクを低減する方法
|
|
CA3118965A1
(en)
*
|
2018-11-16 |
2020-05-22 |
Cymabay Therapeutics, Inc. |
Treatment of obesity and its complications
|
|
SG11202104951RA
(en)
*
|
2018-11-16 |
2021-06-29 |
Cymabay Therapeutics Inc |
Combination treatment of nafld and nash
|
|
CN121081472A
(zh)
|
2018-12-13 |
2025-12-09 |
拓臻股份有限公司 |
一种THRβ受体激动剂化合物及其制备方法和用途
|
|
CA3141807A1
(en)
|
2019-05-31 |
2020-12-03 |
Children's Hospital Medical Center |
Methods of generating and expanding hematopoietic stem cells
|
|
US12398127B2
(en)
|
2019-09-12 |
2025-08-26 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
WO2021097120A1
(en)
|
2019-11-12 |
2021-05-20 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
|
|
US20210145774A1
(en)
*
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Treatment of alcoholic liver disease
|
|
US20210145775A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Treatment of intestinal barrier dysfunction and associated diseases
|
|
US20210379043A1
(en)
*
|
2020-05-13 |
2021-12-09 |
Terns Pharmaceuticals, Inc. |
Combination treatment of liver disorders
|
|
WO2022225896A1
(en)
|
2021-04-21 |
2022-10-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|
|
AU2022274304A1
(en)
*
|
2021-05-11 |
2023-10-26 |
Genfit |
Ppar-agonists for use in the treatment of liver failure
|